AnaptysBio, Inc. (ANAB) vs Urogen Pharma (URGN)

AnaptysBio, Inc. and Urogen Pharma are both Biotechnology companies. AnaptysBio, Inc. and Urogen Pharma are of similar size ($1.5B and $1.4B). Urogen Pharma has negative trailing earnings, so its P/E is not meaningful; AnaptysBio, Inc. trades at 73.6×. Urogen Pharma grew revenue faster over the last twelve months: 159.3% against 95.2%. AnaptysBio, Inc. has the higher net margin (6.54% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, AnaptysBio, Inc. leads on 12 and Urogen Pharma on 4.

Valuation

Metric ANAB URGN Biotechnology median
P/E 73.58 n/m 10.01
P/S 5.66 6.04 9.02
P/B 65.39 n/m 2.13
Price to free cash flow 308.76 n/m 24.99
EV/EBITDA 13.90 n/m 0.64
EV/Sales 5.04 6.44 9.01
Earnings yield 1.36% (4.42%) (34.01%)
Free cash flow yield 0.32% (8.74%) (24.62%)

Profitability

Metric ANAB URGN Biotechnology median
Gross margin 100.00% 91.41% 70.18%
Operating margin 36.14% (12.36%) 0.00%
Net margin 6.54% (26.27%) 0.00%
Free cash flow margin 0.00% (52.77%) 0.00%
Return on equity (365.73%) 54.65% (50.72%)
Return on assets 4.76% (28.78%) (45.56%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ANAB URGN Biotechnology median
Revenue growth (TTM) 95.19% 159.29% 7.42%
EPS growth (last fiscal year) 91.02% (7.77%) 29.36%
Revenue growth, 5-year CAGR 25.62% 56.22% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ANAB URGN Biotechnology median
Debt to equity 0.17 (1.53) 0.00
Current ratio 8.40 3.40 4.72
Net debt to EBITDA (6.84) 0.00 1.01

Dividend

Metric ANAB URGN Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ANAB URGN Biotechnology median
Market cap 1.36b 1.47b 157.22m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack